TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Myung, Jae Kyung | - |
dc.contributor.author | Kwak, Byung Kuk | - |
dc.contributor.author | Lim, Jung Ah | - |
dc.contributor.author | Lee, Myung-Chul | - |
dc.contributor.author | Kim, Min Joo | - |
dc.date.accessioned | 2022-07-15T14:26:49Z | - |
dc.date.available | 2022-07-15T14:26:49Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2016-07 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/154275 | - |
dc.description.abstract | Purpose A telomerase reverse transcriptase (TERT) promoter mutation was identified in thyroid cancer. This TERT promoter mutation is thought to be a prognostic molecular marker, because its association with tumor aggressiveness, persistence/recurrence, and disease-specific mortality in papillary thyroid carcinoma (PTC) has been reported. In this study, we attempted to determine whether the impact of the TERT promoter mutation on PTC persistence/recurrence is independent of clinicopathological parameters. Materials and Methods Using propensity score matching, 39 patients with PTC persistence or recurrence were matched with 35 patients without persistence or recurrence, with a similar age, sex, tumor size, multifocality, bilaterality, extrathyroidal extension, and lymph node metastasis. The TERT promoter and the BRAF V600E mutations were identified from PTC samples. Results The TERT promoter mutation was detected in 18% of PTC patients (13/74). No significant difference in the frequency of the TERT promoter mutation was observed between the persistence/recurrence group and the non-recurrence group. Conclusion These results suggest that the prognostic implications of the TERT promoter mutation are dependent on clinicopathological parameters. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN CANCER ASSOCIATION | - |
dc.title | TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Myung, Jae Kyung | - |
dc.identifier.doi | 10.4143/crt.2015.362 | - |
dc.identifier.scopusid | 2-s2.0-84981352350 | - |
dc.identifier.wosid | 000380496900008 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, v.48, no.3, pp.942 - 947 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.citation.title | CANCER RESEARCH AND TREATMENT | - |
dc.citation.volume | 48 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 942 | - |
dc.citation.endPage | 947 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.identifier.kciid | ART002127313 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | BRAF V600E MUTATION | - |
dc.subject.keywordPlus | TELOMERE LENGTH | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | CARCINOMAS | - |
dc.subject.keywordPlus | RECURRENCE | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordAuthor | Papillary thyroid cancer | - |
dc.subject.keywordAuthor | Telomerase | - |
dc.subject.keywordAuthor | Thyroid neoplasms | - |
dc.identifier.url | https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2015.362 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.